What the trial was testing
The THALES enrolled 11,016 patients with stroke. The study was sponsored by AstraZeneca and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
17% lower risk of stroke or death within 30 days vs. aspirin alone.
New England Journal of Medicine · 2020 · NCT03354429
These findings — that of stroke or death in 30 days when ticagrelor is added to aspirin after mild ischemic stroke or TIA — were published in the New England Journal of Medicine and represent the headline result of the study.
Researchers tracked outcomes across 11,016 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with stroke, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Ticagrelor (Brilinta) plus aspirin is FDA-approved for stroke prevention after a mild stroke or TIA and available now. Treatment is short — usually 30 days — to limit bleeding risk. Talk to a neurologist quickly after stroke symptoms; this regimen only works if started within 24 hours of symptom onset.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open stroke trials
Investigating the Impact of Afferent Stimulation on Proprioceptive Function in Post-Stroke Rehabilitation
The objective of this study is to assess the functionality of a sensory stimulation device that uses mechanical vibrations and low-intensity electrical currents to deliver proprioceptive feedback to stroke patients regarding their movements.
Remote Ischemic Conditioning for Acute Moderate Ischemic Stroke Due to Large Artery Atherosclerosis
Large Artery Atherosclerosis is one of the most prevalent causes of stroke worldwide and is associated with a high risk of disability and recurrent strokes. Remote Ischemic Conditioning (RIC) is a promising therapy, and it has been recommended for further investigation in patients with acute ischemic stroke resulting from large artery atherosclerosis. The primary objective of this study is to assess the efficacy of RIC in patients suffering from acute moderate ischemic stroke due to large artery atherosclerosis.